P4 Precision Medicine Accelerator

Precision (aka personalised) medicine is an emerging approach that takes into account individual variation to predict which treatment/prevention strategies will work in which groups of people. For example, colon cancers that have a normally functioning version of a surface protein called KRAS are likely to respond to certain anti-EGFR antibody therapies; those in which the protein is absent or non-fun. Successful innovation in precision medicine requires several sectors (academia, healthcare and industry) work together - often easier said than done. P4 sits at the intersection of these sectors, leveraging our academic, industry and healthcare connections to create a healthtech ecosystem...

R&d,health technology,investment,academic partnerships,go to market,international markets,ce marking,iso,research,grants,product development,nhs,healthtech,startups,start-ups,start-up,digital heath,healthcare,and venture capital

P4 precision medicine accelerator operates in the Hospitals and health care industry.

P4 precision medicine accelerator's revenue is 11m - 100m

P4 precision medicine accelerator has 11 - 50 employees.